Detection of Genetic Alterations in Pancreatic Cancers by Comparative Genomic Hybridization Coupled with Tissue Microdissection and Degenerate Oligonucleotide Primed Polymerase Chain Reaction (original) (raw)
Article navigation
Research Articles| June 06 2002
aDepartment of Pathology and
bFirst Department of Internal Medicine, Yamaguchi University School of Medicine, Yamaguchi, Japan
Search for other works by this author on:
bFirst Department of Internal Medicine, Yamaguchi University School of Medicine, Yamaguchi, Japan
Search for other works by this author on:
aDepartment of Pathology and
bFirst Department of Internal Medicine, Yamaguchi University School of Medicine, Yamaguchi, Japan
Search for other works by this author on:
aDepartment of Pathology and
bFirst Department of Internal Medicine, Yamaguchi University School of Medicine, Yamaguchi, Japan
Search for other works by this author on:
aDepartment of Pathology and
Search for other works by this author on:
aDepartment of Pathology and
Search for other works by this author on:
aDepartment of Pathology and
Search for other works by this author on:
bFirst Department of Internal Medicine, Yamaguchi University School of Medicine, Yamaguchi, Japan
Search for other works by this author on:
aDepartment of Pathology and
Search for other works by this author on:
Oncology (2002) 62 (3): 251–258.
Abstract
The aim of this study was to elucidate cytogenetic changes in pancreatic cancers (PCs) and to examine their clinical implications. We screened for genetic alterations in 32 primary PCs including 4 cases with distant organ metastasis using comparative genomic hybridization coupled with tissue microdissection and degenerate oligonucleotide primed polymerase chain reaction (DOP-PCR). The present study revealed frequent gains of chromosomes 13q and 15q and a loss of Xq in addition to a high prevalence of chromosomal imbalances. The average number of total genetic alterations and gains tended to be higher in N1 tumors (TNM classification) than in N0 tumors. The average number of amplifications was significantly higher in M1 tumors than in M0 tumors (p = 0.024). Gain/amplification of 20q was more frequently observed in M1 tumors than in M0 tumors (p = 0.016), and this change was also detected in all of 4 distant metastatic lesions. Losses of 6q, 8p, 9p, 17p, and 18q were recurrent in N0 and M0 tumors, and these alterations were also retained in N1 and M1 tumors. These observations suggest that these genetic losses contribute to the development of PCs and that increases in the DNA copy number confer an aggressive character on cancer cells. Especially, gain/amplification of 20q was associated with the potential of distant organ metastasis of tumor cells.
References
Murr MM, Sarr MG, Oishi AJ, van Heerden JA: Pancreatic cancer. CA Cancer J Clin 1994;44:304–318.
Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman FM, Pinkel D: Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992;258:818–821.
Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, Pinkel D: Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosom Cancer 1994;10:231–243.
Solinas-Toldo S, Wallrapp C, Muller-Pillasch F, Bentz M, Gress T, Lichter P: Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization. Cancer Res 1996;56:3803–3807.
Fukushige S, Waldman FM, Kimura M, Abe T, Furukawa T, Sunamura M, Kobari M, Horii A: Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosom Cancer 1997;19:161–169.
Mahlamaki EH, Hoglund M, Gorunova L, Karhu R, Dawiskiba S, Andren-Sandberg A, Kallioniemi OP, Johansson B: Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q and losses of 18q, 9p, and 15q in pancreatic cancer. Genes Chromosom Cancer 1997;20:383–391.
Schleger C, Arens N, Zentgraf H, Bleyl Z, Verbeke C: Identification of frequent chromosomal aberrations in ductal adenocarcinoma of the pancreas by comparative genomic hybridization (CGH). J Pathol 2000;191:27–32.
Hashimoto Y, Oga A, Okami K, Imate Y, Yamashita Y, Sasaki K: Relationship between cytogenetic aberrations by CGH coupled with tissue microdissection and DNA ploidy by laser scanning cytometry in head and neck squamous cell carcinoma. Cytometry 2000;40:161–166.
Kuukasjarvi T, Tanner M, Pennanen S, Karhu R, Visakorpi T, Isola J: Optimizing DOP-PCR for universal amplification of small DNA samples in comparative genomic hybridization. Genes Chromosom Cancer 1997;18:94–101.
Moskaluk CA, Kern SE: Microdissection and polymerase chain reaction amplification of genomic DNA from histological tissue sections. Am J Pathol 1997;150:1547–1552.
Telenius H, Carter NP, Bebb CE, Nordenskjold M, Ponder BAJ, Tunnacliffe A: Degenerate oligonucleotide primed-PCR: General amplification of target DNA by a single degenerate primer. Genomics 1992;13:718–725.
Telenius H, Peimear AH, Tunnacliffe A, Carter NP, Behmel A, Ferguson-Smith MA, Nordenskjold M, Pfragner R, Ponder BAJ: Cytogenetic analysis by chromosome painting using DOP-PCR amplified flow-sorted chromosomes. Genes Chromosom Cancer 1992;4:257–263.
Cheung VG, Nelson SF: Whole genome amplification using a degenerate oligonucleotide primer allows hundreds of genotypes to be performed on less than one nanogram of genomic DNA. Proc Natl Acad Sci USA 1996;93:14676–14679.
Willenbucher RF, Zelman SJ, Ferrell LD, Moore DH II, Waldman FM: Chromosomal alterations in ulcerative colitis-related neoplastic progression. Gastroenterology 1997;113:791–801.
Sanchez-Cespedes M, Cairns P, Jen J, Sidransky D: Degenerate oligonucleotide primed-PCR (DOP-PCR): Evaluation of its reliability for screening of genetic alterations in neoplasia. Biotechniques 1998;25:1036–1038.
Aubele M, Mattis A, Zitzelsberger H, Walch A, Kremer M, Hutzler P, Hofler H, Werner M: Intratumoral heterogeneity of breast carcinoma revealed by laser-microdissection and comparative genomic hybridization. Cancer Genet Cytogenet 1999;110:94–102.
Huang Q, Schantz SP, Rao PH, Mo J, McCormick SA, Chaganti RSK: Improving degenerate oligonucleotide primed PCR-comparative genomic hybridization for analysis of DNA copy number changes in tumors. Genes Chromosom Cancer 2000;28:395–403.
Harada T, Shiraishi K, Kusano N, Umayahara K, Kondoh S, Okita K, Sasaki K: Evaluation of the reliability of chromosomal imbalances detected by combined use of universal DNA amplification and comparative genomic hybridization. Jpn J Cancer Res 2000;91:1119–1125.
Shiraishi K, Okita K, Harada T, Kusano N, Furui T, Kondoh S, Oga A, Kawauchi S, Fukumoto Y, Sasaki K: Comparative genomic hybridization analysis of genetic aberrations associated with development and progression of biliary tract carcinomas. Cancer 2001;91:570–577.
Isola JJ, DeVries S, Chu L, Ghazvini S, Waldman FM: Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol 1994;145:1301–1308.
Nishizaki T, Ozaki S, Harada K, Ito H, Arai H, Beppu T, Sasaki K: Investigation of genetic alterations associated with the grade of astrocytic tumor by comparative genomic hybridization. Genes Chromosom Cancer 1998;21:340–346.
Shiraishi K, Kusano N, Okita S, Oga A, Okita K, Sasaki K: Genetic aberrations detected by comparative genomic hybridization in biliary tract cancers. Oncology 1999;57:42–49.
Shiraishi K, Okita K, Kusano N, Harada T, Kondoh S, Okita S, Ryozawa S, Ohmura R, Noguchi T, Iida Y, Akiyama T, Oga A, Fukumoto Y, Furuya T, Kawauchi S, Sasaki K: A comparison of DNA copy number changes detected by comparative genomic hybridization in malignancies of the liver, biliary tract and pancreas. Oncology 2001;60:151–161.
Sonoda G, Palazzo J, du Manoir S, Godwin AK, Feder M, Yakushiji M, Testa JR: Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosom Cancer 1997;20:320–328.
Sen S, Zhou H, White RA: A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 1997;14:2195–2200.
Ghadimi BM, Schrock E, Walker RL, Wangsa D, Jauho A, Meltzer PS, Reid T: Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas. Am J Pathol 1999;154:525–536.
Vogelstein B, Kinzler KW: The multistep nature of cancer. Trends Genet 1993;9:138–141.
Reid T, Heselmeyer-Haddad K, Blegen H, Schrock E, Auer G: Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: A phenotype/genotype correlation. Genes Chromosom Cancer 1999;25:195–204.
Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27–32.
Ruggeri B, Zhang SY, Caamano J, DiRado M, Flynn SD, Klein-Szanto AJP: Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 1992;7:1503–1511.
Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, Hirohashi S: Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993;142:1534–1543.
Fukushige S, Furukawa T, Satoh K, Sunamura M, Kobari M, Koizumi M, Horii A: Loss of chromosome 18q is an early event in pancreatic ductal tumorigenesis. Cancer Res 1998;58:4222–4226.
Hahn SA, Schutte M, Hoque ATMS, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350–353.
Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE, Hruban RH: Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000;60:2002–2006.
Wilentz RE, Su GH, Dai JL, Sparks AB, Argani P, Sohn TA, Yeo CJ, Kern SE, Hruban RH: Immunohistochemical labeling for DPC4 mirrors genetic status in pancreatic adenocarcinomas. Am J Pathol 2000;156:37–43.
Hohne MW, Halatsch ME, Kahl GF, Weinel RJ: Frequent loss of expression of the potential tumor suppressor gene DCC in ductal pancreatic adenocarcinoma. Cancer Res 1992;52:2616–2619.
Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE: Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731–1734.
Hilgers W, Song JJ, Haye M, Hruban RR, Kern SE, Fearon ER: Homozygous deletions inactivate DCC, but not MADH4/DPC4/SMAD4, in a subset of pancreatic and biliary cancers. Genes Chromosom Cancer 2000;27:353–357.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
Sign in
Digital Version
Pay-Per-View Access
$39.00
1 Karger Article Bundle Token
$150
Rental
This article is also available for rental through DeepDyve. 